Key Takeaways from the CARTITUDE-1 and KarMMa Studies
Focusing on later lines of therapy for patients with relapsed/refractory multiple myeloma, the panel provides key takeaways on the CARTITUDE-1 and KarMMa trials that investigated cilta-cel and ide-cel.
Video content above is prompted by the following questions:
- Please review data from CARTITUDE-1 that led to the approval of ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory multiple myeloma (R/R MM).
- What are some key takeaways for these data?
- Please review data from KarMMa that led to the approval of ide-cel in R/R MM.
- What are some key takeaways from these data?
Recent Videos
Related Content
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
FNU Fatima, MBBS;Faryal Arif, MBBS;Muhammad Hamza Gul, MBBS, MD;Neha Siddiqui, MBBS;Muhammad Zulqarnain, MBBS;Abdul Baseer Wardak, MBBS
November 8th 2024Article
This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
